See What HealthDay Can Do For You
Contact Us

CYP2C19-Genotype Guided Antiplatelet Tx May Be Beneficial

MACE risk up with clopidogrel versus alternative therapy for patients with CYP2C19 loss-of-function allele

listening to heartbeat

FRIDAY, Nov. 3, 2017 (HealthDay News) -- Patients with a CYP2C19 loss-of-function allele have increased risk of major adverse cardiovascular events (MACE) with clopidogrel versus alternative antiplatelet therapy after percutaneous coronary intervention (PCI), according to a study published online Nov. 1 in JACC: Cardiovascular Interventions.

Larisa H. Cavallari, Pharm.D., from the University of Florida in Gainesville, and colleagues examined outcomes following clinical implementation of CYP2C19 genotype-guided antiplatelet therapy after PCI. The authors compared MACE within 12 months of PCI for patients with a loss-of-function allele prescribed clopidogrel versus alternative therapy.

The researchers found that 31.5 percent of the 1,815 patients had a loss-of-function allele. Patients with a loss-of-function allele prescribed clopidogrel had a significantly higher risk for MACE versus those prescribed alternative therapy (23.4 versus 8.7 per 100 patient-years; adjusted hazard ratio, 2.26; 95 percent confidence interval, 1.18 to 4.32; P = 0.013). Among the 1,210 patients with an acute coronary syndrome at the time of PCI, the results were similar (adjusted hazard ratio, 2.87; 95 percent confidence interval, 1.35 to 6.09; P = 0.013). Patients without a loss-of-function allele and loss-of-function allele carriers prescribed alternative therapy had no difference in MACE (adjusted hazard ratio, 1.14; 95 percent confidence interval, 0.69 to 1.88; P = 0.6).

"A future randomized study of genotype-guided antiplatelet therapy may be of value," the authors write.

Two authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.